A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
Study sponsor: PTC Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-06-17Actual
Enrollment · participants359Actual
Source updated2025-06-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.